- Home
- PARA vs BBIO Comparison
PARA vs BBIO Comparison
Compare PARA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PARA
- BBIO
- Stock Information
- Founded
- PARA 1986
- BBIO 2015
- Country
- PARA United States
- BBIO United States
- Employees
- PARA N/A
- BBIO N/A
- Industry
- PARA Broadcasting
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PARA Industrials
- BBIO Health Care
- Exchange
- PARA Nasdaq
- BBIO Nasdaq
- Market Cap
- PARA 7.9B
- BBIO 6.7B
- IPO Year
- PARA N/A
- BBIO 2019
- Fundamental
- Price
- PARA $11.68
- BBIO $34.83
- Analyst Decision
- PARA Sell
- BBIO Strong Buy
- Analyst Count
- PARA 13
- BBIO 12
- Target Price
- PARA $11.42
- BBIO $57.09
- AVG Volume (30 Days)
- PARA 7.4M
- BBIO 3.2M
- Earning Date
- PARA 05-08-2025
- BBIO 04-29-2025
- Dividend Yield
- PARA 1.71%
- BBIO N/A
- EPS Growth
- PARA N/A
- BBIO N/A
- EPS
- PARA N/A
- BBIO N/A
- Revenue
- PARA $29,213,000,000.00
- BBIO $127,415,000.00
- Revenue This Year
- PARA $0.09
- BBIO $13.67
- Revenue Next Year
- PARA $1.13
- BBIO $118.02
- P/E Ratio
- PARA N/A
- BBIO N/A
- Revenue Growth
- PARA N/A
- BBIO N/A
- 52 Week Low
- PARA $9.54
- BBIO $21.62
- 52 Week High
- PARA $13.40
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- PARA 56.56
- BBIO 46.94
- Support Level
- PARA $11.11
- BBIO $36.85
- Resistance Level
- PARA $11.73
- BBIO $39.16
- Average True Range (ATR)
- PARA 0.27
- BBIO 1.47
- MACD
- PARA 0.04
- BBIO -0.07
- Stochastic Oscillator
- PARA 86.36
- BBIO 25.61
About PARA Paramount Global Class B
Paramount Global operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount's streaming platforms is created by the production studios housed within the firm's other two business segments.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.